Lv3
220 积分 2023-02-18 加入
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
1天前
待确认
274MO Pooled efficacy and safety with tremelimumab plus durvalumab in participants (pts) with unresectable hepatocellular carcinoma (uHCC) from the mainland China extension cohort, and Hong Kong (HK) and Taiwan (TW) subgroups from the global cohort in the phase III HIMALAYA study
2个月前
已关闭
Role of N,N,N Trimethyl-L-alanyl-L-proline Betaine Levels in the Process of Myocardial Infarction
2个月前
已关闭
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
2个月前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
3个月前
已完结
LGR5/mTORC2 axis regulates cellular metabolic plasticity to maintain tumorigenesis in hepatocellular carcinoma
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4个月前
已完结
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer
4个月前
已完结
Combination locoregional and systemic therapies in hepatocellular carcinoma
5个月前
已完结
Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug‐coated balloon in a swine femoral artery model
5个月前
已完结
皖公网安备34019202002308
